Feb

2012

Biocartis, SA.: Series C $100M

Posted in I - Series C, Q - 4Q11, R - INTERNATIONAL, X - Device (Diagnostic)

Biocartis (Switzerland) a commercial-stage molecular diagnostics company focused on rapid biomarker identification, closed a $100M Series C financing. Participants include Debiopharm Group, Philips, Johnson & Johnson Development Corp, Wellcome Trust, Korys and Valiance.

Feb

2012

Sera Prognostics, Inc.: Series A $19.3M

Posted in I - Series A, Q - 4Q11, R - ROCKY MOUNTAIN, X - Device (Diagnostic), XX - UT

Sera Prognostics (Salt Lake City, UT) a development-stage diagnostic company focused on preterm birth and other pregnancy complications, closed a $19.3M Series A financing. Participants include InterWest Partners, Domain Associates, Catalyst Health Ventures, UpStart Life Sciences Capital and Osage University Partners.

Feb

2012

Sensors for Medicine and Science, Inc.: Series D $54.1M

Posted in I - Series D, Q - 4Q11, R - MID ATLANTIC, X - Device (Diabetes), X - Device (Diagnostic), XX - MD

Sensors for Medicine and Science (Germantown, MD) a commercial-stage device company focused on implantable, long- term continuous glucose monitoring, closed a $54.1M million in Series D financing. Participants include Delphi Ventures, New Enterprise Associates, HealthCare Ventures, Anthem Capital and Greenspring Associates.

Jan

2012

Aviir, Inc.: Series E $10M

Posted in I - Series E, Q - 4Q11, R - WEST, X - Cardiology, X - Device (Diagnostic), X - Metabolism, XX - CA

Aviir (Irvine, CA) a commercial-stage diagnostic company focused on pharmacogenomic and genetic tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders, closed a $10M Series E financing. Participants include Merck Global Health Innovation, Bay City Capital, Aberdare Ventures and New Leaf Venture Partners.

Jan

2012

NanoString Technologies, Inc.: Series D $20M

Posted in I - Series D, Q - 4Q11, R - NORTH WEST, X - Device (Diagnostic), XX - WA

NanoString Technologies (Seattle, WA) a commercial-stage cell assay device company focused on direct digital detection for gene expression analysis, closed $20M Series D financing. Participants include General Electric, BioMed Ventures, Clarus Ventures, Draper Fisher Jurvetson and OVP Venture Partners.

Jan

2012

Intervention Insights, Inc.: Series B $7.2M

Posted in I - Series B, Q - 3Q11, R - MID WEST, X - Device (Diagnostic), X - Oncology, XX - MI

Intervention Insights (Grand Rapids, MI) a commercial-stage personalized medicine company focused on molecularly targeted oncology therapies, closed a $7.2M Series B financing. Participants include Beringea, Chrysalis Ventures, Hopen Life Science Ventures and Michigan Accelerator Fund.
Thanx for your patience as we catch-up.

Jan

2012

nanoMR, Inc.: Series B $13M

Posted in I - Series B, Q - 3Q11, R - SOUTH WEST, X - Device (Diagnostic), XX - NM

nanoMR (Albuquerque, NM) a development stage medical device focused on a immunomagnetic capture system for the blood culture market, closed a $13M Series B financing. Participants include Excel Venture Management, Healthcare Ventures, vSpring Capital, Dow Chemical Company and Sun Mountain Capital.
Thanx for your patience as we catch-up.

Jan

2012

Intuity Medical, Inc.: Series D $12M

Posted in I - Series D, Q - 3Q11, R - WEST, X - Device (Diabetes), X - Device (Diagnostic), XX - CA

Intuity Medical (Sunnyvale, CA) a clinical-stage diagnostic device company focused on all-in-one blood sample collection and glucose analysis, closed a $12M Series D financing, bringing the total round to $76M. Participants include Accuitive Medical Ventures, Investor Growth Capital, Thomas McNerney, Venrock, Versant Ventures and U.S. Venture Partners.
Thanx for your patience as we catch-up.

Jan

2012

Cleveland Heartlab, Inc.: Series B $18.4M

Posted in I - Series B, Q - 3Q11, R - MID WEST, X - Biomarker, X - Device (Diagnostic), XX - OH

Cleveland Heartlab (Cleveland, OH) a commercial-stage specialty clinical laboratory and disease management company focused on assessing cardiovascular risk, closed a $18.4M Series B financing. Participants include Excel Venture Management and HealthCare Ventures.
Thanx for your patience as we catch-up.

Jan

2012

Horizon Discovery, Ltd.: Series C $18.6M

Posted in I - Series C, Q - 3Q11, R - INTERNATIONAL, X - Device (Diagnostic)

Horizon Discovery (United Kingdom) a commercial-stage translational genomics company focused on drug discovery and molecular diagnostics, closed a $18.6M Series C financing. Participants include MVM Life Sciences, DFJ Esprit and Roche Venture Fund.
Thanx for your patience as we catch-up.

Jan

2012

PathoGenetiX, Inc.: Series B $4M

Posted in I - Series B, Q - 3Q11, R - NORTH EAST, X - Device (Diagnostic), XX - MA

PathoGenetiX (Woburn, MA) a development-stage diagnostic company focused on the identification of pathogenic bacterial strains, closed a $4M Series B financing. Participants include Excel Venture Management, CB Health Ventures and HealthCare Ventures.
Thanx for your patience as we catch-up.

Jan

2012

NanoDetection Technology, Inc. Series A $2.3M

Posted in I - Series A, Q - 3Q11, R - MID WEST, X - Device (Diagnostic), XX - OH

NanoDetection Technology (Cincinnati, OH) a development-stage in vitro poc diagnostic platform focused on uses in healthcare, food safety and bioterrorism, closed a $2.3M Series A financing. Participants include CincyTech.
Thanx for your patience as we catch-up.

Jan

2012

Second Genome, Inc.: Series A $5M

Posted in I - Series A, Q - 3Q11, R - WEST, X - CRO, X - Device (Diagnostic), X - Target ID, XX - CA

Second Genome (San Francisco, CA) a commercial-stage microbial profiling company designed to enable diagnostic/prognostic signatures and target identification, closed a $5M Series A financing. Participants include Advanced Technology Ventures, Morgenthaler Ventures, Wavepoint Ventures and Seraph Group.
Thanx for your patience as we catch-up.

« Previous Entries

to top of page...